生物制剂在免疫相关性肾脏疾病中的应用进展

Application progress of biologics in immune-related renal disease

肾脏疾病因发病机制复杂,现有治疗手段尚不能满足临床需求。随着生物制剂应用的普及,其在肾脏疾病治疗中显示出良好疗效及安全性,为难治性、重症肾病患者提供了新的治疗手段和希望。目前,临床常用的生物制剂包括抗CD20单克隆抗体(利妥昔单抗)、B淋巴细胞刺激因子特异性抑制剂(贝利尤单抗)、抗补体C5单克隆抗体(依库珠单抗)和其他生物制剂(Avacopan)等。文章结合近几年的临床指南及循证医学证据,对这些生物制剂在不同免疫相关性肾脏疾病中的应用进行总结和分析。

Due to the complex pathogenesis of kidney disease,the existing therapeutic methods can not meet the clinical needs.With the popularity of the application of biologics,they have shown good efficacy and safety in the treatment of kidney diseases,providing a new treatment means and hope for patients with refractory and severe kidney disease.Currently,biologics commonly used in clinic include anti-CD20 monoclonal antibody(Rituximab),B-lymphocyte stimulator factor specific inhibitor(Belimumab),anti-complement C5 monoclonal antibody(Eculizumab)and other biologics(Avacopan),etc.This paper summarizes and analyzes the application of these biologics in different immuneassociated renal diseases based on clinical guidelines and evidence-based medical evidence in recent years.